Board of Directors
Kathy Rowlen, Ph.D. Chief Executive Officer and Co-founder
Dr. Kathy Rowlen’s career has spanned both academia and business over the past three decades. Dr. Rowlen was an award winning Professor of Chemistry at the University of Colorado in Boulder from 1991 to 2008; recognition included National Science Foundation Career Award, Beckman Foundation Young Investigator, Research and Creative Work Faculty Fellowship, and Inventor of the Year in 2006. In 2003 Grand Valley State University honored her as a Distinguished Alumna. Dr. Rowlen is inventor/co-inventor on numerous patents, has published over 85 scientific papers, and has given hundreds of scientific talks. After co-founding InDevR in 2003, Dr. Rowlen transitioned to a full time position as its Chief Executive Officer in 2008. Under her leadership the company has experienced balanced growth and has successfully translated fundamental research into high-impact commercial products. InDevR has received a number of awards including Colorado Companies to Watch (2010), Innovative Company of the Year (BizWest IQ Awards, 2015), and Innovative Product of the Year (BizWest IQ Awards, 2015).
Dr. Rowlen received her B.S. (with honors) in Chemistry at Grand Valley State University and her Ph.D. in Chemistry at the University of Colorado, Boulder. She serves on the Board of Directors for InDevR and 2B Technologies.
Shannon Rodriguez Chief Operations Officer
Shannon has led InDevR’s Finance and Operations departments since the company was founded. She has managed more than $30 M in non-dilutive funding and under her leadership the company has consistently and diligently complied with all Federal Acquisition Regulations requirements. Shannon oversees all procurement and subcontracting procedures, financial and account aspects of cost control systems, and compliance with public laws and regulations. Within Operations, she manages facilities and human resources as well as InDevR`s quality system, ensuring company-wide adherence to the quality policy.
Shannon received her B.S. in Business Administration, Operations Management from the University of Colorado, Boulder. She proudly serves as a Board Member for the GO3 Foundation, a novel education program in science, technology and the environment.
Glenn is Founder and Managing Partner at Adjuvant Capital, a life sciences investment firm focused on high-burden and neglected public health challenges. Prior to Adjuvant, Glenn launched and then co-managed the Global Health Investment Fund (GHIF), which was sponsored by the Bill & Melinda Gates Foundation and structured by J.P. Morgan’s Social Finance unit, where Glenn was an Executive Director. He is still active on a number of GHIF projects, including board seats on a number of innovative life sciences companies such as Univercells, Themis, and EuBiologics (listed on KOSDAQ in 2017: 206650.KQ). Glenn also represented GHIF’s interests as a director at IanTech, which was acquired by Carl Zeiss Meditec in 2018.
At Adjuvant, Glenn oversees the firm’s investments in X-Vax (board observer), Themis (board member), and Codagenix (board member), in addition to his InDevR board seat. He is also actively engaged with board member seats at the Research Investment for Global Health Technology Fund (RIGHT Fund) and WaterEquity, where he is a champion of new approaches to financing progress toward achieving the UN Sustainable Development Goals.
Prior to his GHIF/Adjuvant roles, Glenn spent more than a decade as an investment banker at J.P. Morgan, where his practice focused on serving the financing needs of research institutions, charitable foundations, universities, and other non-profit organizations. He earned an AB in public policy from the Woodrow Wilson School of Public & International Affairs at Princeton University.
Michael is a Principal at Adjuvant Capital, a life sciences investment firm focused on high-burden and neglected public health challenges. Prior to Adjuvant, Michael was at the Bill & Melinda Gates Foundation where he worked with the Global Health division to structure investments into biotech companies, leading academic centers, and other non-profit organizations to catalyze technological innovation in global health. Michael has experience investing in the development of drugs, vaccines, diagnostics, and health data solutions across a range of high-burden and neglected disease areas.
Before joining BMGF, Michael spent several years covering the specialty pharmaceuticals sector as an equity research analyst at Piper Jaffray in New York. Michael started his career in the investment banking practice at Stifel where he focused on mergers and acquisitions advising. He earned a BA in International Relations from Johns Hopkins University.
Dr. Buckland is currently the Executive Director of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), Chair of the Board of Engineering Conferences International and the CEO of BiologicB. After obtaining a Ph.D. in Biochemical Engineering from University of College in London, Barry started his career at Abbott Laboratories. He joined Merck in 1980 and quickly moved up the ranks to Vice President of Bioprocess R&D. During his 29 years at Merck he oversaw the successful process development of vaccines against human papilloma virus, shingles, hepatitis A, rotavirus and chicken pox resulting in licensure and successful commercialization.
Since leaving Merck he was leader of the Process Development team at Protein Sciences resulting in the FDA approval of Flublok®; the first recombinant protein-based influenza vaccine. Barry has received numerous accolades for his professional accomplishments, including the Donald Medal from the UK Institute of Chemical Engineering, the Marvin Johnson Award for Biotechnology and election to membership within the prestigious US National Academy of Engineering.